Recursion Pharmaceuticals Inc.
RXRX | NASDAQ
$4.05
+$0.08 (+2.02%)
Sep 22, 2026, 1:24 PM ET · Market open
Market Data
Market Cap $2.08B
Enterprise Value $1.6B
Beta 1.07
Average Volume 19.05M
Shares Outstanding (Diluted) 532.46M
Shares Change YoY 27.58%
Institutional Ownership 63.51%
Exchange NASDAQ
ISIN US75629V1044
Price Performance
Price Change 1M 16.1%
Price Change 3M 25.6%
Price Change 6M 25.2%
Price Change YTD -5.5%
Price Change 1Y -20.3%
Price Change 3Y -49.9%
Price Change 5Y -83.8%
1M CAGR (ann.) 23.3%
1Y CAGR (ann.) -19.5%
5Y CAGR (ann.) -31.4%
All-Time CAGR -24.3%
Valuation
PE Ratio -3.82
Forward PE N/A
PEG Ratio -0.07
Forward PEG 10.61
PS Ratio 37.97
Forward PS 35.50
PB Ratio 2.28
P/FCF Ratio -4.80
P/Adj. FCF Ratio -3.81
P/OCF Ratio -6.02
EV/Sales 29.15
EV/EBIT -3.06
EV/EBITDA -3.60
EV/FCF -3.69
Earnings Yield -26.2%
FCF Yield -20.8%
Adj. FCF Yield -26.2%
Financial Health
Net Cash $545.68M
Total Debt $61.89M
Cash & Short-Term Investments $545.68M
Total Assets $1.21B
Current Ratio 5.03
Quick Ratio 5.03
Debt / Equity Ratio 0.07
Debt / EBITDA -0.14
Debt / FCF -0.14
OCF / Debt -6.97
Interest Coverage -364.62
Altman Z-Score 0.62
Piotroski F-Score 4
Margins & Profitability
Gross Profit Margin -46.7%
Operating Profit Margin -991.7%
EBITDA Margin -810.2%
Net Profit Margin -945.9%
FCF Margin -790.5%
Adj. FCF Margin -996.4%
SBC / Revenue 165.4%
SBC Impact (per share) -26.0%
Returns
Return on Assets -42.8%
Return on Equity -50.4%
Return on Invested Capital -48.3%
Return on Capital Employed -49.8%
Return on Tangible Assets -67.4%
Historical Growth (CAGR)
Revenue CAGR 3Y 3.2%
Revenue CAGR 5Y 45.5%
Revenue CAGR 10Y N/A
EPS CAGR 3Y 19.6%
EPS CAGR 5Y 1.6%
EPS CAGR 10Y N/A
FCF CAGR 3Y -11.3%
FCF CAGR 5Y -24.8%
FCF CAGR 10Y N/A
Analyst Forecasts
Analyst Rating Hold
Analyst Count 10
EPS Growth Next 3Y 3.2%
Revenue Growth Next 3Y 65.2%
Earnings Date Nov 3, 2026
EPS Estimate (next Q) -$0.24
EPS Growth Est (next Q) -33.3%
Revenue Est (next Q) $14.16M
Revenue Growth Est (next Q) 173.6%
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $5.30
Price Target Upside 33.5%
Cash Flow
Operating Cash Flow $-431.58M
Free Cash Flow $-433.63M
Adj. Free Cash Flow $-546.56M
FCF Per Share -$0.67
OCF Per Share -$0.66
OCF/S Ratio -638.9%
Income Statement
Revenue $54.86M
Gross Profit $-25.6M
Operating Income $-544.01M
EBITDA $-444.45M
Net Income $-518.89M
EPS (Diluted) -$1.04
Revenue / Employee $91.43K
Profit / Employee $-864.81K
Employees 600
Add to Watchlist
Select watchlists to add or remove RXRX